Ultragenyx Pharmaceutical Inc. (RARE)
Nasdaq: RARE · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 2011
Who owns Ultragenyx Pharmaceutical Inc.
As filed with the SECHolders of 5% or more
7
Blackrock, Inc. holds 8.3% of Common Stock, as its SCHEDULE 13G/A filed Jul 30, 2026 says.
Directors and officers
15
report now, of 25 people on the record since 2014. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 30, 2026 · Common Stock · 5.1% in Apr 24, 2025
RTW Investments, LP
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, $0.001 par value
Vanguard Portfolio Management
SCHEDULE 13G/A · filed Jul 31, 2026 · Common Stock · 5.5% in Apr 29, 2026
AQR Capital Management, LLC
SCHEDULE 13G · filed Aug 13, 2026 · Common Stock, $0.001 par value
Madison Avenue International LP
SCHEDULE 13G · filed Oct 20, 2026 · Common Stock, $0.001 par value (the "Common Stock")
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 5.1% in May 12, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Sands Capital Management, LLC
SCHEDULE 13G/A · filed Feb 12, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Feb 5, 2026 · COMMON STOCK · reported falling below 5%, from 8.3% in Nov 5, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Feb 10, 2025 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What RARE reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Amlogenyx Inc
An entity · consolidated entity · owns, named in the 10-K filed Feb 18, 2026
15 subsidiaries in 13 countries, from the list filed with the 10-K filed Feb 18, 2026.
Insider tradesForm 4
28sales
0purchases
15sales on a scheduled plan
9people selling
$3.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 19, 2025 to Oct 19, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 19, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 25 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Kakkis Emil D | President & CEO | 1 | $1.2M | 0 | 0 | $0 |
| Horn Howard | Chief Financial Officer | 12 | $1.2M | 11 | 0 | $0 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 5 | $500,000 | 2 | 0 | $0 |
| Crombez Eric | EVP and Chief Medical Officer | 2 | $200,000 | 0 | 0 | $0 |
| Harris Erik | EVP & Chief Commercial Officer | 1 | $200,000 | 0 | 0 | $0 |
| Pinion John Richard | EVP, Chief Quality Operations Officer | 1 | $200,000 | 0 | 0 | $0 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 4 | $100,000 | 1 | 0 | $0 |
| Sanders Corazon (Corsee) D. | director | 1 | $100,000 | 0 | 0 | $0 |
| Suliman Shehnaaz | director | 1 | $100,000 | 1 | 0 | $0 |